RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS

OngoingPhase 2MS (type not specified)2018-000721-31

What was tested

Treatment tested

  • Rituximab

    B-lymphocyte antigen CD20 binding agent

Compared with

  • Rituximab

    B-lymphocyte antigen CD20 binding agent

What it measured

Main measures

  • The primary endpoint of this study is

Other measures (1)

  • The secondary endpoints are

Papers

    Loading reviews and guidelines…

    Related trials

    History

    1. In scope changed from true to false
    1. Started

      Apr 2018

    Assembled by software from public sources.